Stuttering treatment research 1970-2005: II. Systematic review incorporating trial quality assessment of pharmacological approaches

American Journal of Speech-Language Pathology

Volumn 15, Issue 4, 2006, Pages 342-352

  Bothe, Anne K ^a   Davidow, Jason H ^a   Bramlett, Robin E ^a   Franic, Duska M ^a   Ingham, Roger J ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Evidence based practice; Pharmacology; Stuttering; Systematic review; Treatment outcomes

Indexed keywords

EID: 33846046906     PISSN: 10580360     EISSN: 15589110     Source Type: Journal    
DOI: 10.1044/1058-0360(2006/032)     Document Type: Review

References (67)

1. Abwender, D. A., Trinidad, K. S., Jones, K. R., Como, P. G., Hymes, E., & Kurlan, R. (1998). Features resembling Tourette's syndrome in developmental stutterers. Brain and Language, 62, 455-464.
2. Althaus, M., Vink, H., Minderaa, R., Goorhuis-Brouwer, S., & Oosterhoff, A. (1995). Lack of effect of clonidine on stuttering in children. The American Journal of Psychiatry, 152, 1087-1089.
3. American Speech-Language-Hearing Association. (2005). Evidence-based practice in communication disorders [Position statement]. Available from www.asha.org/reference.
4. Andrews, G., & Dosza, M. (1977). Haloperidol and the treatment of stuttering. Journal of Fluency Disorders, 2, 217-224.
5. Bloodstein, O. (1981). A handbook on stuttering (3rd ed.). Chicago: The National Easter Seal Society.
6. Bloodstein, O. (1995). A handbook on stuttering (5th ed.). San Diego, CA: Singular.
7. Bothe, A. K., Davidow, J. H., Bramlett, R. E., & Ingham, R. J. (2006). Stuttering treatment research 1970-2005: I. Systematic review incorporating trial quality assessment of behavioral, cognitive, and related approaches. American Journal of Speech-Language Pathology, 15, 321-341.
8. Brady, J. (1991). The pharmacology of stuttering: A critical review. American Journal of Psychiatry, 148, 1309-1316.
9. Brady, J., & Ali, Z. (2000). Alprazolam, citalopram, and clomipramine for stuttering. Journal of Clinical Psychopharmacology, 20, 287.
10. Brady, J., Price, T., McAllister, T., & Dietrich, K. (1989) A trial of verapamil in the treatment of stuttering in adults. Biological Psychiatry, 25, 626-630.
11. Brady, J. P., & Rynn, M. (1994). Stuttering: Current pharmacological options. CNS Drugs, 1, 263-268.
12. Brin, M., Stewart, C., Blitzer, A., & Diamond, B. (1994). Laryngeal botulinum toxin injection for disabling stuttering in adults. Neurology, 44, 2262-2266.
13. Brumfitt, S. M., & Peake, M. D. (1988). A double-blind study of verapamil in the treatment of stuttering. British Journal of Disorders of Communication, 23, 35-40.
14. Chambless, D. L., & Hollon, S. D. (1998). Defining empirically supported therapies. Journal of Consulting and Clinical Psychology, 66, 7-18.
15. Cochrane, A. L. (1972). Effectiveness and efficiency. Random reflections on health services. London: Nuffield Provincial Hospitals Trust.
16. Cocores, J., Dackis, C., Davies, R., & Gold, M. (1986). Propranolol and stuttering. [Letter to the editor]. The American Journal of Psychiatry, 143, 1071-1072.
17. Comings, D. E., & Comings, B. G. (1994). TS, learning, and speech problems. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 429-430.
18. Conture, E. G., & Guitar, B. E. (1993). Evaluating efficacy of treatment of stuttering: School-age children. Journal of Fluency Disorders, 18, 253-287.
19. Cook, D. J., Guyatt, G. H., Laupacis, A., Sackett, D. L., & Goldberg, R. J. (1995). Clinical recommendations using levels of evidence for antithrombotic agents. Chest, 108(4, Suppl.), 227S-230S.
20. Costa, A. D., & Kroll, R. M. (1995). Sertraline in stuttering. Journal of Clinical Psychopharmacology, 15, 443-444.
21. Costa, D. (1992). Antidepressants and the treatment of stuttering [Letter to the editor]. The American Journal of Psychiatry, 149, 1281.
22. Curlee, R. F. (1993). Evaluating treatment efficacy for adults: Assessment of stuttering disability. Journal of Fluency Disorders, 18, 319-331.
23. Davidow, J. H., Bothe, A. K., & Bramlett, R. E. (2006). The Stuttering Treatment Research Evaluation and Assessment Tool (STREAT): Evaluating treatment research as part of evidence-based practice. American Journal of Speech-Language Pathology, 15, 126-141.
24. Davidow, J. H., Bramlett, R. E., & Bothe, A. K. (2005). Pharmacological Stuttering Treatment Research Evaluation and Assessment Tool (P-STREAT) [Data extraction instrument]. Athens: The University of Georgia.
25. Erickson, R. L. (1969). Assessing communication attitudes among stutterers. Journal of Speech and Hearing Research, 12, 711-724.
26. Gardner, D. M., Baldessarini, R. J., & Waraich, P. (2005). Modern antipsychotic drugs: A critical overview. Canadian Medical Association Journal, 172, 1703-1711.
27. Goberman, A. M., & Blomgren, M. (2003). Parkinsonian speech disfluencies: Effects of L-dopa-related fluctuations. Journal of Fluency Disorders, 28, 55-70.
28. Goldstein, J. A. (1987). Carbamazepine treatment for stuttering [Letter to the editor]. Journal of Clinical Psychiatry, 48, 39.
29. Gordon, C., Cotelingam, G., Stager, S., Ludlow, C., Hamburger, S., & Rapoport, J. (1995). A double-blind comparison of clomipramine and desipramine in the treatment of developmental stuttering. Journal of Clinical Psychiatry, 56, 238-242.
30. Harvey, J., Culatta, R., Halikas, J., Sorenson, J., Luxenberg, M., & Pearson, V. (1992). The effects of carbamazepine on stuttering. Journal of Nervous and Mental Disease, 180, 451-457.
31. Ingham, J. C., & Riley, G. (1998). Guidelines for documentation of treatment efficacy for young children who stutter. Journal of Speech, Language, and Hearing Research, 41, 753-770.
32. Ingham, R. J. (1984). Stuttering and behavior therapy: Current status and experimental foundations. San Diego, CA: College-Hill Press.
33. Ingham, R. J. (1998). On learning from speech-motor control research on stuttering. In A. K. Cordes & R. J. Ingham (Eds.), Treatment efficacy for stuttering: A search for empirical bases (pp. 67-101). San Diego, CA: Singular.
34. Ingham, R. J., & Cordes, A. (1997). Self-measurement and evaluating stuttering treatment efficacy. In R. F. Curlee & G. M. Siegal (Eds.), Nature and treatment of stuttering: New directions (2nd ed., pp. 413-437). Boston: Allyn & Bacon.
35. Ingham, R. J., & Costello, J. M. (1984). Stuttering treatment outcome evaluation. In J. M. Costello (Ed.), Speech disorders in adults: Recent advances (pp. 189-223). San Diego, CA: College-Hill Press.
36. Klasco, R. K. (Ed.). (2004). USP DI®: Drug information for the healthcare professional. Greenwood Village, CO: Thomson Micromedex.
37. Kymissis, P., & Martin, E. (1990). Antistuttering medication? [Letter to the editor]. Journal of American Academic Child and Adolescent Psychiatry, 29, 840.
38. Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2004). Drug information handbook (12th ed.). Hudson, OH: Lexi-Comp/APhA.
39. Lavid, N., Franklin, D., & Maguire, G. (1999). Management of child and adolescent stuttering with olanzapine: Three case reports. Annals of Clinical Psychiatry, 11, 233-236.
40. Maguire, G. A., Gottschalk, L. A., Riley, G. D., Franklin, D. L., Bechtel, R. J., & Ashurst, J. (1999). Stuttering: Neuropsychiatric features measured by content analysis of speech and the effect of risperidone on stuttering severity. Comprehensive Psychiatry, 40, 308-314.
41. Maguire, G., Riley, G., Franklin, D., & Gottschalk, L. (2000). Risperidone for the treatment of stuttering. Journal of Clinical Psychopharmacology, 20, 479-482.
42. Maguire, G. A., Yu, B. P., Franklin, D. L., & Riley, G. D. (2004). Alleviating stuttering with pharmacological interventions. Expert Opinion on Pharmacotherapy, 5, 1565-1571.
43. Moscicki, E. K. (1993). Fundamental methodological considerations in controlled clinical trials. Journal of Fluency Disorders, 18, 183-196.
44. Oberlander, E., Schneier, F., & Liebowitz, M. (1993). Treatment of stuttering with phenelzine [Letter to the editor]. American Journal of Psychiatry, 150, 355.
45. Oxford Centre for Evidence-Based Medicine. (2006). Levels of evidence and grades of recommendation. Retrieved March 3, 2006, from http://www.cebm.net/levels_of_evidence.asp.
46. Prins, D., Mandelkorn, T., & Cerf, F. A. (1980). Principal and differential effects of haloperidol and placebo treatments upon speech disfluencies in stutterers. Journal of Speech and Hearing Research, 23, 614-629.
47. Rantala, S. L., & Petri-Larmi, M. (1976). Haloperidol (serenase) in the treatment of stuttering. Folia Phoniatrica, 28, 354-361.
48. Riley, G. D. (1994). Stuttering Severity Instrument for Children and Adults, Third Edition. Austin, TX: Pro-Ed.
49. Rosenberger, P. B., Wheelden, J. A., & Kalotkin, M. (1976). The effect of haloperidol on stuttering. American Journal of Psychiatry, 133, 331-334.
50. Rothenberger, A., Johannsen, H., Schulze, H., Amorosa, H., & Rommel, D. (1994). Use of tiapride on stuttering in children and adolescents. Perceptual and Motor Skills, 79, 1163-1170.
51. Rustin, L., Kuhr, A., Cook, P., & James, I. (1981). Controlled trial of speech therapy versus oxprenolol for stammering. British Medical Journal, 283, 517-519.
52. Sackett, D. L., Straus, S. E., Richardson, W. S., Rosenberg, W., & Haynes, R. B. (2000). Evidence-based medicine: How to practice and teach EBM (2nd ed.). New York: Churchill Livingstone.
53. Sallee, F. R., Nesbitt, L., Jackson, C., Sine, L., & Sethuraman, G. (1997). Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. American Journal of Psychiatry, 154, 1057-1062.
54. Sandor, P. (2003). Pharmacological management of tics in patients with TS. Journal of Psychosomatic Research, 55, 41-48.
55. Schiavetti, N., & Metz, D. E. (2002). Evaluating research in communicative disorders (4th ed.). Boston: Allyn & Bacon.
56. Shumak, I. C. (1955). A speech situation rating sheet for stutterers. In W. Johnson & R. R. Leutennegger (Eds.), Stuttering in children and adults: Thirty years of research at the University of Iowa (pp. 341-347). Minneapolis: University of Minnesota Press.
57. Silverstone, T. (1970). The use of drugs in behavior therapy. Behavior Therapy, 1, 487-497.
58. Smith, A., Denny, M., Shaffer, L. A., Kelly, E. M., & Hirano, M. (1996). Activity of intrinsic laryngeal muscles in fluent and disfluent speech. Journal of Speech and Hearing Research, 39, 329-348.
59. Stager, S. V., Calis, K., Grothe, D., Bloch, M., Berensen, N. M., Smith, P. J., & Braun, A. (2005). Treatment with medications affecting dopaminergic and serotonergic mechanisms: Effects on fluency and anxiety in persons who stutter. Journal of Fluency Disorders, 30, 319-335.
60. Stager, S., Ludlow, C., Gordon, C., Cotelingam, M., & Rapoport, J. (1995). Fluency changes in persons who stutter following a double blind trial of clomipramine and desipramine. Journal of Speech and Hearing Research, 38, 516-525.
61. Sweetman, S. C. (Ed.). (2004). Martindale: The complete drug reference. Greenwood Village, CO: Thomson Micromedex.
62. Swift, W., Swift, E., & Arellano, M. (1975). Haloperidol as a treatment for adult stuttering. Comprehensive Psychiatry, 16, 61-67.
63. Vink, H., Althaus, M., Goorhuis-Brouwer, S., & Minderaa, R. (1992). Clonidine and stuttering [Letter to the editor]. American Journal of Psychiatry, 149, 717.
64. Wells, P. G., & Malcolm, M. T. (1971). Controlled trial of the treatment of 36 stutterers. British Journal of Psychiatry, 119, 603-604.
65. Wickersham, R. M., & Novak, K. K. (Eds.). (2005). Drug facts and comparisons. St. Louis, MO: Wolters Kluwer Health.
66. Woolf, G. (1967). The assessment of stuttering as struggle, avoidance, and expectancy. British Journal of Disorders of Communication, 2, 158-171.
67. Wu, J. C., Maguire, G., Riley, G., Lee, A., Keator, D., Tang, C., et al. (1997). Increased dopamine activity associated with stuttering. Neuroreport, 8, 767-770.